NCT00847899

Evaluation of Soluble Epoxide Hydrolase (s-EH) Inhibitor in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Exploratory, 28-Day Study to Examine the Effects of AR9281 on Blood Pressure and Glucose Tolerance in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 150 (estimated)
• Sponsor: Arete Therapeutics · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the safety and efficacy of AR9281, a novel s-EH enzyme inhibitor, in improving glucose metabolism and blood pressure in patients with impaired glucose tolerance and mild to moderate hypertension.

Conditions

• Hypertension
• Impaired Glucose Tolerance

Interventions

Type	Name	Description
DRUG	AR9281	AR9281 taken in BID dosing regimen for 28 days
DRUG	AR9281	AR9281 taken in TID dosing regimen for 28 days
DRUG	Placebo	Placebo taken in BID dosing regimen for 28 days
DRUG	Placebo	Placebo taken in TID dosing regimen for 28 days

Timeline

• Start date: 2009-01-01
• Primary completion: 2009-10-01
• Completion: 2009-11-01
• First posted: 2009-02-19
• Last updated: 2009-11-20

Locations

30 sites across 1 country: United States